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To the Editor: 
We read with interest the recently published article by Stoevesandt et al about 
the over- and underestimated parameters in Hymenoptera-induced anaphylaxis. 
In this article, the authors report that the absence of urticaria/angioedema is an 
indicator for severe anaphylaxis and possibly also for mastocytosis, requiring 
assessment of baseline serum tryptase. Despite the large number of cases 
analyzed, authors mainly focused their goal on the evaluation of risk factors for 
severe anaphylaxis due to Hymenoptera field stings, particularly as regards 
details related to the sting reactions and concurrent medication. Conversely, 
they did not screen for mastocytosis in their series, and the potential association 
between the absence of hives during anaphylaxis and mastocytosis was 
supported only by studies including a limited number of cases, most of which 
had urticaria pigmentosa (UP). Because of this, we call the authors’ and 
readers’ attention to several previous studies that have investigated the 
association between anaphylaxis and mastocytosis. On the basis of a 
multivariate logistic regression analysis, we have previously identified risk 
factors associated with systemic mastocytosis (SM) in patients with severe mast 
cell (MC) mediator-release symptoms including cases with anaphylaxis referred 
to the Reference Center of the Spanish Network on Mastocytosis (REMA). In 
our study published in 2010, a simple and efficient score model for predicting 
SM was proposed (REMA score), which was further validated prospectively in 
the largest series of patients with SM lacking UP reported so far. In these 
studies, we already demonstrated that the absence of urticaria and angioedema 
and the presence of dizziness and/or syncope during anaphylaxis, together with 
increased baseline serum tryptase levels and male gender, are independent 
predictors for an underlying SM in these patients. Noteworthy, all patients 
included in our studies lacked UP, which further emphasizes the clinical utility of 
the REMA score and demonstrated that the severity of anaphylaxis is most 
likely due to the presence of clonal MC rather than the absence of cutaneo-
mucosal symptoms itself. Similarly, elevated baseline serum tryptase levels in 
patients with a history of anaphylaxis should be rather considered as an 
epiphenomenon of the enhanced MC activation and/or relatively increased MC 
numbers than a true risk factor for the severity of anaphylaxis, such risk being 
most frequently conferred by an underlying clonal MC disorder. Table I details 
the distribution of the REMA score parameters in our updated series of patients 
with hymenoptera-induced anaphylaxis (n = 71) who were screened for SM. It 
should be emphasized that SM without UP associated to anaphylaxis is 
characterized by low bone marrow (BM) MC burden, which typically results in 
the absence of BM MC aggregates in a significant proportion of patients. In this 
scenario, cytomorphological characterization of MC in BM smears is frequently 
hampered by their limited numbers and their preferential location within BM 
particles; therefore, highly-sensitive diagnostic methods including 
multiparameter flow cytometry immunophenotyping for the identification of low 
numbers of aberrant BM MCs, together with analysis of the KIT mutation in 
highly purified BM MC fractions,7 become specially relevant in the study of 
suspected clonal MC disorders without UP associated to anaphylaxis. 
TABLE I. Distribution of parameters included in the REMA score in 71 patients with 
Hymenoptera sting anaphylaxis in the absence of UP, according to the presence 
versus absence of an underlying SM 
 
                                                    ISM patients                          Non-ISM patients  
                                               (n=60)                                 (n=11)                         P value 
Male gender                           51 (85)                                  7 (63)                            NS 
Urticaria*                               12 (20)                                    6 (55)                           .02  
Angioedema*                       3 (5)                                          7 (64)                          <.001 
Dizziness*                                51(85)                                  8(73)                               NS 
Syncope*                                 41(68)                                    1(9)                            <.001 
BST                                    22.4 (6.8-217)                       15 (4.6-39.5)                    .006 
Median score value (range)     5(0-7)                                 1(-4 to 7)                        .001 
 
Note. Results expressed as number of cases and percentage in parentheses or as 
median and range between parentheses.  
BST, Baseline serum tryptase; ISM, indolent SM without skin lesions; NS, not 
significant. 
*Clinical symptoms observed during acute anaphylactic episodes. 
